Clinical trial · Observational
Theranostic PET for Target Validation and Tumor Detection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department. The aim of this study is to collect data on the expression of target molecules/receptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET/CT or PET/MRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions. Primary Endpoint: Association between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with solid malignancies
- description
- performing diagnostic PET/CT with a novel theranostic tracer
Primary outcomes (1)
- measure
- Association between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.
- timeFrame
- 12 months
Secondary outcomes (6)
- measure
- Proportion of tumor manifestations with uptake in theranostic PET on a per-lesion, per-region, and per-patient basis
- timeFrame
- 12 months
- measure
- Detection rate and PPV of theranostic PET on a per-patient and per-region-basis, confirmed by histopathology, clinical and conventional imaging follow-up
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine 2. Age ≥ 18 years Exclusion Criteria: 1. Patient cannot give consent for the study 2. Patient cannot lie flat or tolerate PET imaging 3. Unwillingness or inability to comply with study and follow-up procedures 4. Condition of patient which is critical to participate in this study in the discretion of the investigators 5. Pregnant, lactating, or breast-feeding women
References
Publications (0)
Data not yet available